Literature DB >> 20041322

Pharmacokinetics of intravenous omeprazole in critically ill paediatric patients.

Maria Jose Solana1, Jesús López-Herce.   

Abstract

The proton pump inhibitors are first-line drugs for the treatment of a number of gastrointestinal diseases. These drugs have a good safety profile, making it possible to use them in paediatric patients. Although their pharmacokinetics in children has not been extensively studied, research performed suggests that the dose used should be varied as a function of age, as this factor affects the drug's metabolism. Proton pump inhibitors can be used in critically ill children for the prophylaxis and treatment of gastrointestinal haemorrhage, although there is still little experience with this. The most widely used proton pump inhibitor at the present time is omeprazole. As there are specific characteristics of these patients that could alter the pharmacokinetics of the drugs, studies need to be performed to determine the most suitable dose and dosage interval.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20041322     DOI: 10.1007/s00228-009-0774-9

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  42 in total

1.  Frequency and prophylaxis of upper gastrointestinal hemorrhage in critically ill children: a prospective study comparing the efficacy of almagate, ranitidine, and sucralfate. The Gastrointestinal Hemorrhage Study Group.

Authors:  J López-Herce; P Dorao; P Elola; M A Delgado; F Ruza; R Madero
Journal:  Crit Care Med       Date:  1992-08       Impact factor: 7.598

Review 2.  Proton pump inhibitors: an update of their clinical use and pharmacokinetics.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2008-08-05       Impact factor: 2.953

3.  A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.

Authors:  Sarah C Sim; Carl Risinger; Marja-Liisa Dahl; Eleni Aklillu; Magnus Christensen; Leif Bertilsson; Magnus Ingelman-Sundberg
Journal:  Clin Pharmacol Ther       Date:  2006-01       Impact factor: 6.875

Review 4.  Pharmacogenetics in pediatrics. Implications for practice.

Authors:  J S Leeder; G L Kearns
Journal:  Pediatr Clin North Am       Date:  1997-02       Impact factor: 3.278

5.  CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans.

Authors:  T Furuta; K Ohashi; K Kosuge; X J Zhao; M Takashima; M Kimura; M Nishimoto; H Hanai; E Kaneko; T Ishizaki
Journal:  Clin Pharmacol Ther       Date:  1999-05       Impact factor: 6.875

6.  Effect of dietary bulk on small intestinal morphology and cell renewal in the rat.

Authors:  R Ecknauer; B Sircar; L R Johnson
Journal:  Gastroenterology       Date:  1981-10       Impact factor: 22.682

7.  High prevalence of asymptomatic esophageal and gastric lesions in preterm infants in intensive care.

Authors:  M Mäki; T Ruuska; A L Kuusela; R Karikoski-Leo; R S Ikonen
Journal:  Crit Care Med       Date:  1993-12       Impact factor: 7.598

Review 8.  An overview of proton pump inhibitors.

Authors:  Gabriella Der
Journal:  Gastroenterol Nurs       Date:  2003 Sep-Oct       Impact factor: 0.978

Review 9.  Proton pump inhibitors in GORD An overview of their pharmacology, efficacy and safety.

Authors:  Vincenzo Savarino; Francesco Di Mario; Carmelo Scarpignato
Journal:  Pharmacol Res       Date:  2008-10-08       Impact factor: 7.658

10.  Effect of intravenous and oral omeprazole on 24-hour intragastric acidity in duodenal ulcer patients.

Authors:  C Cederberg; A B Thomson; V Mahachai; J A Westin; P Kirdeikis; D Fisher; L Zuk; B Marriage
Journal:  Gastroenterology       Date:  1992-09       Impact factor: 22.682

View more
  2 in total

Review 1.  Clinical Pharmacology Studies in Critically Ill Children.

Authors:  Nilay Thakkar; Sara Salerno; Christoph P Hornik; Daniel Gonzalez
Journal:  Pharm Res       Date:  2016-09-01       Impact factor: 4.200

2.  Effect of Elevated pH on the Commercial Enteric-Coated Omeprazole Pellets Resistance: Patent Review and Multisource Generics Comparison.

Authors:  Valentyn Mohylyuk; Anna Yerkhova; Marina Katynska; Vitaliy Sirko; Kavil Patel
Journal:  AAPS PharmSciTech       Date:  2021-06-22       Impact factor: 3.246

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.